Curated News
By: NewsRamp Editorial Staff
April 22, 2025
Calidi Biotherapeutics to Host Investor Webinar on Stem Cell-Based Oncolytic Virus Therapies
TLDR
- Calidi Biotherapeutics to host investor webinar featuring new Chief Medical Officer, highlighting stem cell-based delivery platforms for oncolytic virus therapies.
- Calidi's technology utilizes allogeneic stem cells to carry oncolytic viruses for various oncology indications, aiming to enhance efficacy and patient safety.
- Calidi's innovative approach empowers the immune system to combat cancer, potentially treating metastatic disease and improving patient outcomes.
- Learn about Calidi Biotherapeutics' cutting-edge stem cell-based therapies and their potential to revolutionize cancer treatment during the live investor webinar.
Impact - Why it Matters
This news matters as it highlights advancements in cancer treatment technology, potentially improving patient outcomes and safety in combatting high-grade gliomas and solid tumors. Investors and individuals interested in innovative oncology solutions should pay attention to this event.
Summary
Calidi Biotherapeutics (NYSE American: CLDI) will host a live investor webinar featuring new Chief Medical Officer, Dr. Guy Travis Clifton, to discuss stem cell-based delivery platforms for oncolytic virus therapies. Updates on FDA-cleared CLD-201, CLD-400, and CLD-101 will be provided, with a live Q&A session to follow.
Calidi Biotherapeutics specializes in empowering the immune system to combat cancer using allogeneic stem cells carrying oncolytic viruses. The company's off-the-shelf delivery platforms aim to enhance efficacy and safety in treating various oncology indications.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Calidi Biotherapeutics to Host Investor Webinar on Stem Cell-Based Oncolytic Virus Therapies
